Innate Pharma Announces €30 Million Share Offering

Innate Pharma, listed on Euronext Paris and Nasdaq, has announced the pricing of a €30 million offering of new ordinary shares. The company plans to issue 17,647,059 shares at €1.70 each, a decision based on recent trading figures with a 15% price reduction. The offering targets qualified European investors and selected institutional investors in the U.S.

Stifel is coordinating, alongside BTIG, the transaction which should close by August 18, 2026. The net proceeds of €27.6 million will support the development of IPH4502 and the company's preclinical ADC portfolio.

Investors in this round will influence a 18.76% capital dilution. Bpifrance Participations has committed to a €3 million investment. The company expects to extend its financial resources until early 2028, with additional support from a strategic partnership with Sobi.